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De Novo Prediction of PTBP1 Binding and Splicing
Targets Reveals Unexpected Features of Its RNA
Recognition and Function
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Abstract
The splicing regulator Polypyrimidine Tract Binding Protein (PTBP1) has four RNA binding domains that each binds a short
pyrimidine element, allowing recognition of diverse pyrimidine-rich sequences. This variation makes it difficult to evaluate
PTBP1 binding to particular sites based on sequence alone and thus to identify target RNAs. Conversely, transcriptome-wide
binding assays such as CLIP identify many in vivo targets, but do not provide a quantitative assessment of binding and are
informative only for the cells where the analysis is performed. A general method of predicting PTBP1 binding and possible
targets in any cell type is needed. We developed computational models that predict the binding and splicing targets of
PTBP1. A Hidden Markov Model (HMM), trained on CLIP-seq data, was used to score probable PTBP1 binding sites. Scores
from this model are highly correlated (r = 20.9) with experimentally determined dissociation constants. Notably, we find
that the protein is not strictly pyrimidine specific, as interspersed Guanosine residues are well tolerated within PTBP1
binding sites. This model identifies many previously unrecognized PTBP1 binding sites, and can score PTBP1 binding across
the transcriptome in the absence of CLIP data. Using this model to examine the placement of PTBP1 binding sites in
controlling splicing, we trained a multinomial logistic model on sets of PTBP1 regulated and unregulated exons. Applying
this model to rank exons across the mouse transcriptome identifies known PTBP1 targets and many new exons that were
confirmed as PTBP1-repressed by RT-PCR and RNA-seq after PTBP1 depletion. We find that PTBP1 dependent exons are
diverse in structure and do not all fit previous descriptions of the placement of PTBP1 binding sites. Our study uncovers new
features of RNA recognition and splicing regulation by PTBP1. This approach can be applied to other multi-RRM domain
proteins to assess binding site degeneracy and multifactorial splicing regulation.
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not currently feasible, in part due to our incomplete understanding
of RNA recognition by the splicing regulators and their
mechanisms of action.
Whole-transcriptome crosslinking methods for individual proteins in vivo are allowing the identification of large numbers of
protein/RNA interaction sites [8,9,10,11]. These data can be
overlapped with functional data on splicing to identify possible
direct target exons for particular proteins [12,13,14,15]. However,
there are limitations in the interpretation of these data. Crosslinking efficiency can vary between different proteins and between
individual binding sites, making it difficult to relate the crosslinking
signal to the actual binding affinity. These signals are also
dependent on the expression of the bound RNA, and since these
data are generated one tissue or cell type at a time it is not always
feasible to extend the results from one setting to a new cell type or
point in development. It would be extremely useful to be able to
scan for binding affinity across the complete transcriptome and to

Introduction
Alternative splicing of pre-mRNA commonly determines the
protein output of mammalian genes, with most genes generating
multiple mRNA and protein products [1]. A typical alternative
exon is affected by multiple pre-mRNA binding proteins that may
either enhance or repress splicing [2]. The expression and activity
of these splicing regulatory proteins can vary with development,
cell type, or cellular stimulus [3]. This complex combinatorial
regulation can be seen in the conserved sequences within and
surrounding alternative exons, which generally contain the
binding sites for many different regulators. These sequences make
up what is sometimes called the splicing code as they determine
where and when the exon is spliced into an mRNA [4,5,6,7]. Such
a code should allow the development of models that predict exon
regulation based solely on the RNA binding affinity of the many
regulatory proteins and their other interactions. However, this is
PLOS Computational Biology | www.ploscompbiol.org
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elements for each domain are not known. Moreover, the flexible
linkers separating some of the RRM domains and the requirement
for a gap between elements simultaneously bound to domains
three and four allow for substantial degeneracy in PTBP1 binding
sites. This degeneracy and the lack of understanding of the
sequence features that contribute to binding affinity have made it
difficult to identify PTBP1 binding sites based on sequence alone,
and to assess which sequences surrounding an exon might
contribute to PTBP1 regulation.
Experiments with model substrates indicate that a single high
affinity PTBP1 binding site placed upstream of an exon, or within
it, can repress splicing [27]. However, strong repression of an
efficiently spliced exon requires an additional binding site either
within the exon or downstream from an exon with an upstream
high affinity site [17,27,28]. PTBP1 is also known to enhance the
splicing of certain exons [13,19,20]. The properties of these exons
and how they differ from those that are repressed by PTBP1 are
unclear, with different studies coming to different conclusions
[13,19]. An analysis of CLIP data in HeLa cells found that PTBP1
sites near the adjacent constitutive exons could enhance the
inclusion of an alternative exon between them [13]. In contrast,
examination of exons whose splicing was reduced by double
knockdown of Ptbp1 and Ptbp2 found that they frequently had
binding sites immediately downstream [19], whereas splicing
repression often involved upstream binding sites: a pattern
observed for other splicing regulators. These results are not
mutually exclusive. It is possible that the two groups examined
different subsets of the many exons regulated by PTBP1, and that
the protein may show additional patterns of protein binding
adjacent to its target exons.
In this study we sought to understand the sequence features that
determine RNA binding by PTBP1 and to examine how they are
combined in exons that are targeted by the protein. We first
developed a statistical model of PTBP1 binding sites that identifies
new features of RNA recognition by the protein. This binding
model was then applied to the assessment of exon regulation by
PTBP1 across the transcriptome.

Author Summary
A key step in the regulation of mammalian genes is the
splicing of the messenger RNA precursor to produce a
mature mRNA that can be translated into a particular
protein needed by the cell. Through the process of
alternative splicing, mRNAs encoding different proteins
can be derived from the same primary gene transcript. The
regulation of this process plays essential roles in the
development of differentiated tissues and is mediated by
special pre-mRNA binding proteins. To understand how
these proteins control gene expression, one must characterize what they recognize in RNA and identify these
binding sites across the genome in order to predict their
targets. Models that allow this prediction are essential to
understanding developmental regulatory programs and
their perturbation by disease causing mutations. In this
study, we use statistical methods to build models of RNA
recognition by the important splicing regulator PTBP1 and
then apply these models to predict PTBP1 regulation of
new gene transcripts. We show that PTBP1 has different
specificity for RNA than was previously recognized and
that its target exons are more diverse than was known
before. There are many similar splicing regulators in
mammalian cells, and these analyses provide a general
framework for the computational analysis of their RNA
binding and target identification.
predict exon targets in tissues that have not yet been subjected to
experimental analysis.
Splicing regulatory proteins commonly contain multiple RRM or
other RNA binding domains, with each domain recognizing a short
element of a few nucleotides [2,16]. Subtle variation in the optimal
binding element of each domain and flexible peptide linkers
between them allow for significant degeneracy within high affinity
binding sites. Although the short sequence motifs that are common
to a set of binding sites are readily identified, these likely constitute
only a portion of a full high affinity site. To rank binding sites and
assess their finer structures, we need an approach to search for
clusters of these short motifs and to score for binding affinity.
The Polypyrimidine tract binding protein 1 (PTBP1) is a widely
studied splicing regulatory protein [17,18]. PTBP1 is known to
repress the splicing of a large number of exons by binding in their
adjacent introns or within the exons themselves. PTBP1 is down
regulated in differentiating neurons and muscle cells to allow
inclusion of PTBP1 repressed exons during development of these
tissues [19,20,21]. In neurons the loss of PTBP1 is accompanied by
the up-regulation of the homologous protein PTBP2 [17,20,22].
PTBP2 has similar binding properties to PTBP1 and represses
some of the same exons [23]. Other exons are more sensitive to
PTBP1 than PTBP2 and are induced to splice when PTBP2
replaces PTBP1 in early neurons [24].
PTBP1 contains four RRM domains that recognize short
pyrimidine elements [25]. Flexible linkers separate RRM domains
one and two, and domains two and three. RRM domains three
and four interact through a hydrophobic interface that position
their RNA binding surfaces on opposite faces of the two-domain
structure. This orientation requires that the RNA elements
interacting with the structure be separated by an RNA loop
[26]. The structure of each of the PTBP1 RRM domains has been
solved in complex with the hexanucleotide, CUCUCU [25].
These structures show each domain binding a nucleotide triplet
with some additional contacts, and making similar base specific
interactions with CU or UC dinucleotides. Other sequences can
likely make different base specific contacts, and the optimal
PLOS Computational Biology | www.ploscompbiol.org

Results
G containing triplets contribute to PTBP1 binding
To examine the interactions of PTBP1 across many binding
sites, we used a set of PTBP1-bound sequences identified by
crosslinking immunoprecipitation (CLIP) [13]. PTBP1 has four
RRMs separated by linker peptides, with each RRM recognizing a
pyrimidine triplet. In previous studies we found that a minimal
high affinity binding site for the protein extended across 25 to 30
nucleotides, about the average size of the CLIP clusters (29 nt)
[27]. Given the triplet recognition and the need for spacers
between the direct RRM contacts, it is unlikely that every
nucleotide within a CLIP cluster makes a direct base-specific
contact with the protein or otherwise contributes to binding
affinity. This information about direct binding is hidden in the
examination of a CLIP tag, but should affect the triplet frequencies
within the entire set of tags. We designed a two-state Hidden
Markov Model (HMM) based on triplets to assess whether triplets
would segregate into two states and whether these two states
differed in their PTBP1 binding or non-binding potential. The
48,604 CLIP clusters from the human transcriptome were
extracted and used to train the HMM (Figure 1A) [29,30]. This
training defined two states showing distinctly different triplet
distributions (Figure 1B). Pleasingly, all of the pyrimidine triplets
segregated into State 1. We called this state the PTBP1 binding
state, as we confirm below. We found that 20 triplets have higher
2
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Figure 1. PTBP1 binding model. A. Scheme of the PTBP1 binding model. The two-state HMM model was trained on PTBP1 bound RNA sequences
(48,604 clusters) from published PTBP1-CLIP experiments. Triplets from these CLIP clusters were predictive of two states, with all of the pyrimidine
triplets preferred by State 1. The diagram presents the structure of the PTBP1 HMM (Hidden Markov Model) and its trained transition probabilities. B.
The probabilities that triplets are seen states 1 or 2 (emission probabilities) are plotted in black and gray bars, respectively. Asterisks indicate G
containing pyrimidine triplets.
doi:10.1371/journal.pcbi.1003442.g001

of its RRM domains can presumably make specific contacts with
G residues. On the other hand, all A containing triplets have
modest positive emission probabilities for state 2 and are likely to
be either neutral or to inhibit PTBP1 binding.
We next tested the HMM scoring, which strongly weights the
triplets from state 1 over state 2, for prediction of PTBP1 binding.
We performed cross validation experiments on the Hela CLIP
dataset. A background dataset was generated using ten randomly
picked sequences from each gene identified as containing a CLIP
cluster. Applying the model to this data set gave us a distribution of
scores that was compared to scores generated by subsets of the
CLIP clusters removed from the training set prior to training. As
shown in Figure S1, sequences from subsets of the CLIP clusters
scored significantly higher than background.

probabilities to be seen in the PTBP1 binding state. All triplets
containing only pyrimidines were included in this 20-triplet set
(Figure 1B), with the top-scoring triplet UCU showing the
alternating C and U nucleotides seen in many characterized
PTBP1 binding sites.
Interestingly, multiple triplets containing G residues are also
preferred in State1 (Figure 1B). These triplets often contain U
residues as the other nucleotides. Some of these triplets, such as
UGU, have output (emission) probabilities in State 1 that are
similar to pyrimidine triplets, presumably also making them
predictive of PTBP1 binding. In contrast, triplets containing A
residues, even if the other two nucleotides are pyrimidines, were all
preferred by the non-PTBP1 binding State 2. These results
indicate that PTBP1 is not strictly pyrimidine specific. At least one
PLOS Computational Biology | www.ploscompbiol.org
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We also tested our model on an independent iCLIP dataset
from human embryonic stem cells (ESC) (Figure S2). Unlike
standard CLIP, iCLIP tags define the probable crosslink site as
being the 59 terminus of the tag. We used a Viterbi algorithm to
predict the most probable state path predicted by the PTBP1
HMM model for each iCLIP tag. Defining triplets from the State1
(PTBP1 binding) and triplets from State 2 (nonbinding), we found
that the frequency of predicted binding triplets is highly enriched
in the iCLIP cluster regions and peaks precisely at the crosslink
site. This indicates that State 1 probability is highly associated with
PTBP1 crosslinking in vivo.
To more quantitatively assess the relationship between the
HMM score and RNA binding, we applied the trained model to a
set of 100,000 random 69 nucleotide sequences. This length allows
for one hexanucleotide binding site for each of the four RRMs
with 15 nucleotide gaps, the minimum gap required for
simultaneous binding by RRMs 3 and 4 [25,26]. The scores are
calculated as a log-odds ratio of the probabilities of the sequence
having been generated by the HMM over a background model
that assigns equal probability to all triplets. The random sequences
generated a distribution of scores that was used to normalize the
binding scores, with the average score for random sequence set to
zero, and the z-score defined as the deviation from the average as
shown in Figure S3A [29]. Thus a sequence with a z-score of 2.74
is 2.74 standard deviations from the average (empirical
p-value = 0.005), and is predicted to be a significantly stronger
binder than the average sequence (500 of the 100,000 random
sequences have scores equal or greater than this sequence). A
negative z-score is predicted to bind less well than the average
sequence. We isolated thirteen sequences from the mouse
transcriptome that exhibited a range of scores from 22.62 to +
4.40 (Figure 2A). These were transcribed in vitro and subjected to
electrophoretic mobility shift assay to measure binding to
recombinant PTBP1 (Figure 2B; Figure S3B). Sequences yielding
negative scores all failed to bind PTBP1 within the protein
concentration range tested, with the exception of probe 4, which
bound weakly, below the level that would allow measurement of
an affinity constant. Positive scoring sequences all yielded PTBP1
bound complexes that were assayable by gel shift to derive
apparent binding affinities. The apparent Kds of these RNAs
showed a very strong negative correlation with their binding score
from the model (Pearson correlation coefficient = 2 0.9), where a
higher score predicts a lower Kd and hence a higher affinity
(Figure 2A). Thus, the scoring system performed very well in
predicting PTBP1 binding affinity.
Two sequences (probes 9 and 11) showed variable binding that
shifted their Kd’s slightly off the fitted curve relating z-score to Kd.
These may have secondary structures that reduce binding affinity
thus increase their apparent Kd. To look at this, we examined the
predicted structure of each probe using the RNA fold program
[31]. Probes 9 and 11 did not show an overall free energy of
folding substantially lower than other RNAs. However, it is
difficult to rule out that they contain a local structure that
sequesters some key feature for PTBP1 recognition.
In addition to the background model using uniform triplet
frequencies, we also tested control sequence sets using different
nucleotide frequencies (Figure S4). Control sets that maintain the
mono or dinucleotide frequencies of the PTBP1 CLIP tags while
shuffling the triplet frequencies did not perform well. This is not
surprising because these sequences are highly skewed in nucleotide
content and the shuffling does not change the triplet frequencies
dramatically. We also tested a background model based on
random sequences selected from genes containing PTBP1 CLIP
clusters (ten sequences from each gene). Like the random dataset,
PLOS Computational Biology | www.ploscompbiol.org

this background model generated scores that predicted affinity
reasonably well. However, it did generate negative scores for a
couple of probes that are shown to bind (data not shown). Thus,
the uniform model gave the most accurate scoring of the
background models we tested.
The data demonstrate that HMM scoring based on triplet
frequencies can accurately predict the observed binding affinities
across a wide range of Kd values (from ,250 nM to 1 nM). Probe
6 yields a z-score of 0.82 and binds with a Kd of 257 nM, whereas
probe 10 scores 2.74 in the model and binds with a Kd of 73 nM
(Figure 2B). These sequences include G containing triplets that
contribute to the binding scores. This method allows any sequence
to now be quantitatively assessed for possible PTBP1 binding,
which was not previously possible by simply looking for clusters of
a limited number of motifs. This HMM based approach should be
applicable to the prediction of binding sites and affinity for other
multi-domain RNA binding proteins.

Placement of PTBP1 binding sites adjacent to target
exons
With our new method of defining PTBP1 binding sites, we next
examined PTBP1 target exons for the location of predicted PTBP1
binding. In part, we wanted to reassess two previous studies that
came to differing conclusions regarding the placement of PTBP1
sites adjacent to its target exons. One group mapped PTBP1 CLIP
clusters adjacent to a limited number of PTBP1 repressed and
enhanced exons [13]. This study described PTBP1 repressed
exons as enriched for binding sites both upstream and downstream, as has been seen in studies of individual exons. They did
not observe PTBP1 CLIP clusters within repressed exons, even
though such exons have been described [17,32,33]. The PTBP1
enhanced exons they examined showed a trend in PTBP1 binding
near the flanking constitutive exons. A second study examined
exons showing altered splicing on splicing-sensitive microarrays
after Ptbp1/Ptbp2 double knockdown [19]. CLIP clusters derived
from the first study were mapped to these exons. The authors
found CLIP cluster enrichment upstream and within PTBP1/
PTBP2 repressed exons. In contrast to the previous study, they
found that PTBP1/PTBP2 enhanced exons showed enrichment
for CLIP tags in the downstream region. This pattern of binding
site placement relative to repressed and enhanced exons has been
observed for several other splicing regulatory proteins [14,34].
In our study, we defined four groups of exons from a set of
exons previously assessed for splicing after Ptbp1 knockdown
[20,35]. These included 68 PTBP1-repressed exons whose splicing
increases after Ptbp1 knockdown, 37 PTBP1-enhanced exons
whose splicing decreases after knockdown, 69 control exons that
are not affected by Ptbp1 depletion but are known to be
alternatively spliced (PTBP1-non regulated), and 1,000 constitutive exons. We determined the density of predicted PTBP1
binding states within a 24-nucleotide window sliding along the
exon region. We also examined the sequence encompassing the
adjacent constitutive exons (Figure 3A). As expected, the nonregulated control and constitutive exon sets did not exhibit high
probabilities of PTBP1 binding except in the polypyrimidine tract
of the 39 splice site. On the other hand, the introns upstream of
PTBP1 repressed exons show enrichment of potential PTBP1
binding sites starting from 250 nucleotides upstream of the exon.
Relative to the control exons, exons repressed by PTBP1 also
exhibited substantial enrichment of PTBP1 binding sites within the
exon itself and within the first 100 nucleotides of the downstream
intron. The repressed exons thus exhibit binding site placement
that combines the findings of the two previous studies [13,19]. The
PTBP1-enhanced exon set also shows enrichment of PTBP1
4
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Figure 2. Validation of the PTBP1 binding model. A. To validate binding scores, thirteen RNAs with various PTBP1 binding scores were transcribed
in vitro and subjected to binding assay. Apparent Kd’s (dissociation constant) were highly negatively correlated with PTBP1 binding scores (Pearson
correlation = 20.9). B. Four RNA sequences with predicted PTBP1 binding scores (Full data binding data in Figure S3). Potential PTBP1 binding sites are
underlined and in bold. Experimental binding affinities were assessed by electrophoretic mobility shift of RNA by PTBP1 and compared with prediction
scores. Apparent dissociation constants (Kd) were defined as the concentration at which half the protein was bound to RNA.
doi:10.1371/journal.pcbi.1003442.g002

binding sites within the downstream intron relative to control
exons, although the distribution of binding sites across this region
was different between the repressed and enhanced exon sets

PLOS Computational Biology | www.ploscompbiol.org

(Figure 3A). Similar to what was seen in the previous study by
Llorian, we found little enrichment of PTBP1 sites within
enhanced exons [19]. There is a limited enrichment adjacent to

5
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Figure 3. Sequence characteristics of PTBP1-dependent alternatively spliced exons. A. An RNA map shows enrichment of predicted
PTBP1 binding sites near PTBP1-dependent exons. The Y-axis plots average density of predicted PTBP1 binding states within a 24 nt window; the
length of overlap between two adjacent windows was 8 nt. B. To assess PTBP1 binding signatures of individual exons, known PTBP1 regulated exons
were clustered by their PTBP1 binding score profiles and visualized as heat maps. These heat maps indicate wide variation in the positions of PTBP1
binding sites between individual exons. C. Four sequence features including the PTBP1 binding scores and 39 splice site strength show statistically
significant differences between regulated and control exon groups (one-tailed Student’s t-tests).
doi:10.1371/journal.pcbi.1003442.g003
PLOS Computational Biology | www.ploscompbiol.org
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to consider many different factors. Nevertheless, models based on
single factors will be useful for understanding the relative
contributions of individual proteins to patterns of splicing
regulation. Such models will be easier to interpret regarding the
contributions of individual factors to individual exons than more
complex models. Moreover in the longer term, models developed
for different individual factors can be combined to make more
accurate predictions. To assess how well one might model splicing
regulation by a single factor, we examined whether the strength
and placement of predicted PTBP1 binding sites could be used to
predict new PTBP1 dependent exons. We plotted the scores for a
variety of sequence features against the percent of exons exhibiting
that score that also exhibit PTBP1 dependent exon repression
(Figure S5). These plots produced distinct sigmoidal curves where
most exons regulated by PTBP1 were found above or below a
particular score. This strongly suggests that a logistic regression
model incorporating each of these scores will be predictive of
PTBP1 repression.
We developed a multinomial logistic regression model and
trained it on three classes of regulated exons (Figure 4A) [38]. The
training set included PTBP1 repressed exons, PTBP1 enhanced
exons, and non-regulated exons. Each exon in each class was
scored for the four features found to correlate with PTBP1
regulation (x1 through x4), including the 39 splice site strength, and
the PTBP1 binding scores for each of three regions: the 250
nucleotides upstream of the exon, the exon itself, and the 100
nucleotides downstream of the exon. These intron lengths
encompass the regions of binding site enrichment for PTBP1
dependent exons (Figure 3).
The PTBP1-enhanced exons are fewer in number and show
more limited enrichment of PTBP1 binding sites than PTBP1repressed exons making the prediction for these exons less accurate.
We first tested models that considered just PTBP1-repressed exons
relative to control groups. However, we found that including the
enhanced exons as a separate training group improved the
prediction of repressed exons, even though enhanced exons
themselves are not as easily identified (data not shown).
The trained model yielded values for the b coefficients that
weight the different features contributing to the regulation. As
expected the upstream binding score was weighted most heavily in
predicting PTBP1 repression (Table S1), although binding scores in
all three regions contributed to the score for PTBP1 repression. In
contrast, we found that only the downstream binding score was
significantly associated with PTBP1 enhancement. The upstream
score generated a b coefficient close to zero making it essentially
neutral in the prediction of enhanced exons. The exon binding score
was subject to a negative b coefficient, indicating that exon binding
reduces the probability of PTBP1 enhancement. Using these b
coefficients, the trained models for repression or enhancement each
yield a value of the g-function (logit) for an exon (x) given by the log
of the ratio of the probability of repression or enhancement over the
probability that the exon is not regulated. From this, the probability
that an exon is repressed by PTBP1 can be determined from the two
g-values as shown in Figure 4A.
We assessed the multinomial logistic regression model by
recursively retraining on exon sets with one exon left out and
then scoring the missing exon. This leave-one-out cross validation
enabled assessment of the overall performance of the model [38]
(Figure S6). The PTBP1 dependent exon repression logit showed
good prediction, with an area under the curve (AUC) value of
0.72, substantially greater than random guessing (AUC = 0.5). As
expected, the enhanced exon logit was not as accurate as the
repression logit (AUC = 0.57), although it was better than random
(Figure S6A). Using these data, we assessed the sensitivity and

the exons flanking enhanced exons. Interestingly however, we find
some PTBP1 enhanced exons that have PTBP1 binding sites
upstream of the exon. These were not seen in either previous
study. Our results are generally consistent with the known
placement of PTBP1 binding sites in PTBP1 target exons and
imply that rules correlating the position of PTBP1 binding to its
effect on a target exon are not as strict as seen for some other
splicing regulators. The mechanisms proposed from previous maps
of PTBP1 binding do not appear to be generalizable to all PTBP1
targets [13,19,27].
Binding maps for PTBP1 and other splicing regulators show the
averages of multiple exons. Since the data indicated a high level of
variability in binding site placement between individual exons, we
wanted to visualize target exons relative to each other. To display
binding signals for individual exons we created heat maps of the
binding scores upstream, within, and downstream of each exon in
the PTBP1 target set (Figure 3B). This display makes clear that the
location of PTBP1 binding sites within its known target exons is
variable. We found that 60% of PTBP1 repressed exons are
predicted to have strong binding sites within the upstream intron.
Most of these exons also have strong binding sites within either the
exon or the downstream intron, patterns that were observed
previously [13,19,27]. However, other patterns of binding site
placement are also seen, suggesting PTBP1 dependent exons are
following multiple rules. Some repressed exons score highly for
PTBP1 binding only within the exon or in both the exon and the
downstream intron. About half of PTBP1 enhanced exons have
strong PTBP1 binding sites downstream (Figure 3B). These can
co-occur with upstream intron-binding sites, but rarely with exon
binding sites. Interestingly, there are exons enhanced by PTBP1
with strong upstream binding in the absence of other sites. These
data demonstrate the heterogeneity in the position of PTBP1
binding sites for its target exons. This heterogeneity needs to be
considered for predicting PTBP1 dependent regulation.
PTBP1 repressed exons exhibited significantly higher average
binding scores in both the upstream intron and in the exon itself,
than either the control group of alternative exons or the PTBP1
enhanced exons (Figure 3C). The average binding scores in the
downstream introns were higher for both the PTBP1-repressed
and PTBP1-enhanced exons than the control group (Figure 3C),
although not at the same statistical significance. The variability of
binding site placement within the smaller group of PTBP1enhanced exons presumably contributes to the weaker statistical
correlation of binding scores with positive regulation.
We also compared the three exon sets for other features that
might contribute to their ability to be regulated by PTBP1,
including exon length, flanking intron length, and 59 and 39 splice
site strength. Most of these features were not statistically different
among the three-exon groups. However, both PTBP1 enhanced
and PTBP1 repressed exons were found to carry significantly
weaker 39 splice sites than the control exon set, as measured by the
Analyzer Splice Tool (Figure 3C) [36,37].
These results indicate that PTBP1-repressed exons, and perhaps
PTBP1-enhanced exons, exhibit an ensemble of sequence features
that define them as PTBP1 regulated and that should allow their
identification by sequence alone.

Prediction of PTBP1 repressed exons
Alternative exons are generally regulated by multiple factors
that act both positively and negatively on their ability to be spliced.
Thus, an exon controlled by a regulator in one context might not
be affected by it under other conditions where counteracting
factors are present, or required cofactors are absent. This means
that the most accurate predictions of splicing regulation will need
PLOS Computational Biology | www.ploscompbiol.org
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Figure 4. Scheme of the PTBP1 splicing regulation model and its application to an exon in Ptbp3. A. The PTBP1 splicing regulation model
was trained on known PTBP1-regulated and non-regulated exons and used to predict new PTBP1-dependent exons. Prediction results were
compared to changes in exon inclusion (PSI) measured by RT-PCR and RNA-seq. An exon from Ptbp3 is presented as a prediction example. From
intron and exon sequences, PTBP1 binding scores and 39 splice site strength were calculated and fed into the regulation model. B. The model
predicts exon 2 of Ptbp3 as repressed by PTBP1 with high probability (0.89). Ptbp1 knockdown in mouse neuroblastoma cells (N2A) confirmed
de-repression of the exon (from PSI = 45 to PSI = 70).
doi:10.1371/journal.pcbi.1003442.g004

specificity across the range of scores to define a decision threshold
for exon repression scores (Figure S6B). Increasing the threshold
increases the specificity by eliminating many false positives, but
decreases the sensitivity of the model in identifying maximum
PLOS Computational Biology | www.ploscompbiol.org

numbers of repressed exons. We sought to choose a threshold that
gave a low false positive rate over one that yielded more regulated
exons. We found that above a threshold score of 0.65 the false
positive rate was 10% or lower (Figure S6B).
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Applying the model to 4494 alternative cassette exons from
UCSC genome browser database, we found 243 exons (5.4%) that
yielded a PTBP1 repression probability score greater than 0.65 and
which were not in the training set. The 50 top-scoring cassette exons
are listed in Table 1. These included two exons that were reported
previously to be PTBP1 targets. An exon of Gabrg2 yields a
probability score of 0.92. Although we could not confirm its
repression in N2A cells because of low expression of the transcript,
the orthologous exon in rat is a well-characterized PTBP1
repression target [39]. Exon 2 of Ptbp3 (Rod1), another known
PTBP1 target [40], yielded a repression probability score of 0.89
and was confirmed by RT/PCR to show increased inclusion after
Ptbp1 knockdown (Figure 4B). We performed additional RT-PCR
validation in triplicate on a series of high and low scoring exons from
transcripts expressed in N2A cells (Figure 5 & Figures S7, S8 and
S9). Seven of ten exons scoring above 0.65 were de-repressed after
Ptbp1 knockdown in N2A cells, yielding a validation rate of 70%.
The actual false positive rate is difficult to estimate because exons
with high repression scores that are not affected by Ptbp1 depletion
in N2A cells might be regulated by PTBP1 in other cells. An
indication that this might be occurring is that the average inclusion
level (or percent spliced in value, PSI) of the putative false positives is
significantly higher than the confirmed true positives in N2A cells,
indicating that they will be less prone to change upon Ptbp1
depletion and be more difficult to validate (Figure S8B). Thus, the
true positive rate may be greater than 70%. Importantly, the high
validation rate for exons scoring above 0.65 indicates that the
binding model and the regulation model based upon it can identify
many new PTBP1 targets that were not previously known (Table1).
High scoring exons might also fail to be validated because of
regulation by other proteins. Knockdown of Ptbp1 induces
expression of its close homolog Ptbp2, which targets some of the
same exons [20] (Figure S7). To test whether PTBP2 was also
targeting the predicted PTBP1 repressed exons, we knocked down
Ptbp2 or both Ptbp1 and Ptbp2 expression in N2A cells and reassayed the exons in triplicate (Figures S10, S11 & S8A). Although
some exons showed greater inclusion in the double knockdown
compared to depletion of Ptbp1 alone, this did not validate any
additional predicted PTBP1 repressed exons. We did identify some
high and low scoring exons showing more complex regulation by
the two PTB proteins (Figure S10 & S11).
We also examined a set of low scoring exons (probability score#
0.2) by RT-PCR after Ptbp1 and/or Ptbp2 depletion (Figure 5B
and Figure S11). All of these exons (8 of 8) failed to respond to the
loss of PTBP1 and are likely true negatives. Thus, PTBP1
repression scores above 0.65 and below 0.2 were highly predictive
for regulation and its absence, respectively. As expected, intermediate scores were less consistent in their predictive value (Figure
S9). Some exons in the intermediate scoring group were affected
by PTB proteins and will be interesting to assess further.
The prediction of PTBP1-repressed exons was improved by
treating PTBP1-enhanced exons as a separate class, but the
probability scores for PTBP1 enhancement did not consistently
identify new PTBP1 target exons (data not shown). This is likely in
part due to the smaller number of exons in the training set and
their heterogeneity, with some possibly being indirect targets.
These predictions will likely improve with training on larger
numbers of PTBP1 enhanced exons as they are identified.
However, it is possible that simply the presence of the PTBP1
binding site is not sufficient for predicting PTBP1 enhancement
and that binding sites for other factors will need to be considered.
We next tested the model on a genomewide scale, by applying it
to a set of 168,111 mouse internal exons and ranking them by their
probability of PTBP1 repression. This analysis yielded 3824 exons
PLOS Computational Biology | www.ploscompbiol.org

(2.3%) with probability scores above 0.65 for being repressed by
PTBP1. Among other activities, these exons were enriched in
genes that function in calcium ion transport, cytoskeletal
organization, intracellular transport, and synaptic transmission,
all functions affected by previously known PTB targets (Table S2).
To assess splicing of this large set of predicted PTB targets, we
used RNA-seq to generate a large dataset of exons that change after
Ptbp1 knockdown. RNA from control and PTBP1-depleted N2A
cells was subjected to high density short read sequencing on the
Illumina HiSeq platform using a strand specific, paired end protocol
[41]. Exons whose inclusion changed between the two samples were
identified by alignment to an exon database and quantification of
exon inclusion using the SpliceTrap program [42]. After filtering for
read coverage and removing the training set, we identified 573
alternative exons whose splicing was assayable in N2A cells. These
exons exhibit changes in percent exon inclusion (delta PSI) ranging
from 229% to 62% upon PTBP1 depletion. The exons were
binned by their PTBP1 repression probability scores and plotted for
their change in PSI (Figure 6). The average changes in splicing were
significantly correlated with the repression probability. Exons
scoring below 0.5 distributed around zero change in PSI, but above
this score the average exon inclusion is altered by PTBP1 depletion.
Most notably, exons with a repression probability score above 0.65
exhibited significantly larger changes in splicing than exons with
lower scores. Exons with intermediate scores and hence weaker
binding sites show smaller changes in splicing than high scoring
exons. Setting a threshold of a 5% change in PSI as validation, 22 of
33 exons (67%) that scored above 0.65 for PTBP1 regulation were
confirmed as PTBP1 repression targets in N2A cells. At least some
of the other 11 exons are presumably PTBP1 targets in other cells.
To test the model in another cell type, we examined exons
reported to change after Ptbp1 knockdown in mouse C2C12
myoblasts, as measured on splicing sensitive microarrays [43]. Very
similar to what was observed in N2A cells, we found that exons with
high repression probabilities showed significant de-repression upon
the Ptbp1 knockdown compared to exons with low repression
probabilities (Figure S12). Of 29 exons assayed on the arrays with a
repression probability above 0.65, 19 exons were confirmed as
PTBP1 repressed on the array (q-value,0.05), yielding a validation
rate of 66%. Thus the model performed very similarly in C2C12
and N2A cells. Among the 11 high scoring exons identified as
unchanged after PTBP1 knockdown in N2A cells only 3 were
assayed on the array and expressed in C2C12 cells. These again
showed high inclusion in C2C12 prior to knockdown and so were
difficult to assay for derepression. Thus, it is difficult to use the
C2C12 data to draw conclusions about the false positive rate.
The logistical model gives us a new tool for studying the
regulation of alternative splicing. Using it, we can now scan genomic
sequence to score exons for PTBP1 regulation. Applying the model
genomewide, the PTBP1 repression probability scores were
integrated into the UCSC genome browser. These data, displayed
with the RNAseq data from N2A cells are available at our website
(http://www.mimg.ucla.edu/faculty/black/ptbatweb/). A novel
PTBP1 repressed exon in the Kcnq2 gene is shown in Figure 6B.
The logistic model thus allows the assessment of any exon across the
transcriptome for likely PTBP1 regulation.

Discussion
New features of PTBP1 binding sites
We have developed two computational models, one that allows
accurate prediction of PTBP1 binding sites and another that
predicts likelihood of PTBP1 repression of exons across the
transcriptome. These models uncovered several new features of
9
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Table 1. PTBP1 repressed exons identified by the splicing model.

Gene Name

Gene Description

PTB Binding Scores

mm9 coordinates

Upstream
Intron
(250 nt)

Exon

39
Downstream

Splice site

Intron
(100 nt)

Strength

p(Repressed)

Pax6

paired box gene 6

chr2:105523985–105524115(+)

8.35

21.49

20.80

0.27

0.99

Mbd5

methyl-CpG binding
domain protein 5

chr2:49134101–49135303(+)

6.46

20.93

2.27

20.32

0.98

Arhgap24

Rho GTPase activating
protein 24

chr5:102981145–102981338(+)

6.47

0.10

20.05

0.46

0.97

Tle1

transducin-like enhancer
of split 1

chr4:71819247–71819451(2)

4.71

0.05

21.26

22.56

0.94

Acsl6

acyl-CoA synthetase
long-chain family

chr11:54150438–54150515(+)

4.16

1.40

20.03

20.82

0.94

Ryr1

ryanodine receptor 1,
skeletal muscle

chr7:29829938–29829955(2)

4.78

20.08

20.88

21.71

0.94

Ankhd1

ankyrin repeat and KH
domain containing 1

chr18:36784163–36784921(+)

4.37

0.03

1.44

20.64

0.93

Slc39a14

solute carrier family 39
(zinc transporter)

chr14:70713408–70713577(2)

3.51

1.16

21.27

23.20

0.92

Gabrg2

gamma-aminobutyric
acid (GABA) A receptor

chr11:41727472–41727495(2)

1.95

2.77

0.56

23.79

0.92

Itga7

integrin alpha 7

chr10:128378878–128378997(+)

4.14

0.29

1.13

20.25

0.92

Iqsec2

IQ motif and Sec7
domain 2

chrX:148615540–148615635(+)

4.88

0.68

20.13

0.71

0.91

Smarca2

SWI/SNF related,
matrix associated,
actin dependent regulator
of chromatin

chr19:26825612–26825646(+)

3.94

20.09

1.23

20.86

0.91

Zfand3

zinc finger, AN1-type
domain 3

chr17:30197755–30197795(+)

4.17

2.34

0.90

1.80

0.91

Agap2

ArfGAP with GTPase
domain, ankyrin repeat
and PH domain 2

chr10:126527198–126527257(+)

3.57

0.06

20.53

23.08

0.90

Ttn

Titin

chr2:76723554–76723832(2)

2.93

1.06

1.19

21.83

0.90

Ptbp3

ROD1 regulator
of differentiation
1 (S. pombe)

chr4:59559021–59559054(2)

3.80

0.57

1.66

0.73

0.89

Mapk8

mitogen-activated
protein kinase 8

chr14:34203859–34203930(2)

2.35

1.17

1.01

23.48

0.89

Snap91

synaptosomal-associated
protein 91

chr9:86693373–86693534(2)

2.60

1.89

20.35

22.17

0.88

Fmnl1

formin-like 1

chr11:103059449–103059547(+)

3.93

20.60

21.36

22.70

0.88

Phldb1

pleckstrin homology-like
domain, family B

chr9:44509029–44509169(2)

3.20

0.57

1.05

20.66

0.87

2310035C23Rik

RIKEN cDNA 2310035C23
gene

chr1:107637012–107637094(+)

2.03

1.76

0.85

22.46

0.87

Arnt

aryl hydrocarbon receptor
nuclear translocator

chr3:95270715–95270759(+)

3.48

20.36

2.53

0.09

0.87

Smyd2

SET and MYND domain
containing 2

chr1:191723697–191723807(2)

3.33

0.33

20.28

21.64

0.86

Ap2a1

adaptor protein complex
AP-2, alpha 1 subunit

chr7:52158832–52158897(2)

3.35

20.12

20.89

22.69

0.86

Klra

killer cell lectin-like
receptor, subfamily A

chr6:130329011–130329100(2)

2.82

3.18

0.62

0.77

0.86

Spag9

sperm associated
antigen 9

chr11: 93942054–93942068(+)

0.99

3.01

1.62

23.03

0.86

Col4a3bp

collagen, type IV,
alpha 3 binding protein

chr13:97386949–97387026(+)

2.81

1.23

0.74

20.93

0.86

Garnl3

GTPase activating
RANGAP domain-like 3

chr2:32941395–32941464(2)

4.15

0.38

0.36

0.94

0.86
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Table 1. Cont.

Gene Name

Gene Description

PTB Binding Scores

mm9 coordinates

Upstream

39
Downstream

Splice site

Intron
(250 nt)

Exon

Intron
(100 nt)

Strength

p(Repressed)

Dennd1a

DENN/MADD domain
containing 1A

chr2:37982049–37982168(2)

3.37

0.80

1.35

0.59

0.86

Ms4a7

membrane-spanning
4-domains, subfamily A

chr19:11400297–11400353(2)

2.79

2.35

0.37

20.05

0.86

BC030307

cDNA sequence BC030307

chr10:86169981–86170089(+)

2.75

20.16

1.95

22.40

0.85

Phactr1

phosphatase and actin
regulator 1

chr13:43154940–43155146(+)

2.73

1.25

0.50

20.97

0.85

R3hdm2

R3H domain containing 2

chr10:126902187–126902240(+)

1.66

1.98

1.96

21.57

0.84

Cdc14b

CDC14 cell division
cycle 14B

chr13:64306579–64306725(2)

1.42

2.75

2.44

20.58

0.84

Ubqln1

ubiquilin 1

chr13:58282183–58282266(2)

2.88

0.98

20.06

21.17

0.84

Ttn

Titin

chr2:76739898–76740179(2)

2.63

20.07

1.49

22.38

0.84

Stx3

syntaxin 3

chr19:11857290–11857400(2)

3.00

21.12

2.26

23.62

0.84

Slc8a3

solute (sodium/calcium)
carrier family 8

chr12: 82310340–82310458(2)

1.84

1.25

1.76

22.25

0.84

Zfp62

zinc finger protein 62

chr11:49028057–49028156(+)

3.27

1.98

20.51

0.19

0.83

Dlg1

discs, large homolog 1
(Drosophila)

chr16:31771843–31771941(+)

1.53

1.98

1.87

21.65

0.83

Nrxn2

neurexin II

chr19:6463824–6463847(+)

3.35

21.37

1.33

22.26

0.83

Klra7

killer cell lectin-like
receptor, subfamily A

chr6:130179953–130180042(2)

2.68

2.11

20.39

20.63

0.83

Picalm

phosphatidylinositol
binding clathrin assembly

chr7:97330729–97330878(+)

1.15

2.15

2.30

22.37

0.83

Acad8

acyl-Coenzyme A
dehydrogenase family

chr9:26798168–26798277(2)

2.61

0.88

20.31

21.86

0.83

Epn1

epsin 1

chr7:5033620–5033723(+)

3.92

0.65

0.07

1.06

0.82

Grip1

glutamate receptor
interacting protein 1

chr10:119422530–119422685(+)

2.66

20.74

2.61

23.13

0.82

Csmd3

CUB and Sushi multiple
domains 3

chr15:47587514–47587627(2)

2.42

2.16

0.20

20.45

0.82

Lrrfip1

leucine rich repeat (in FLII)
interacting protein 1

chr1:92990137–92990214(+)

2.02

0.40

3.44

22.21

0.82

Srsf11

serine/arginine-rich
splicing factor 11

chr3:157703405–157703586(+)

1.09

2.05

20.56

24.75

0.82

Tmem209

transmembrane
protein 209

chr6:30441087–30441184(2)

3.82

0.16

0.10

0.64

0.82

The 50 highest scoring exons predicted to be repressed by PTBP1 based on sequence alone.
doi:10.1371/journal.pcbi.1003442.t001

The base-specific contacts that PTBP1 makes with Guanosine
are not yet clear. Recent studies of RNA recognition by SRSF2
(SC35) protein have shown that the element GGAG can be
recognized by the same RRM as CCAG by flipping the initial two
G nucleotides to the syn conformation [45]. It will be very
interesting to investigate whether a similar anti to syn switch
occurs in RNA bound by PTBP1, when C residues are replaced
with G.
Previous characterizations of PTBP1 binding sites have focused
on finding enriched short motifs within populations of bound
RNAs or regulated exon sequences [13,44,46,47,48]. These
methods generally identify elements whose short length will allow
interaction with only one RRM domain. Searching for new
binding sites comprised of clusters of these short elements can

RNA recognition by PTBP1 and the properties of its target exons.
The PTBP1 binding model was based on triplets following the
structures of the PTBP1 RRM domains, whose sequence specific
contacts are each primarily to three nucleotides. We find that the
set of triplets that increase the probability of binding includes the
expected pyrimidine motifs, particularly those with alternating
cytosines and uridines. However, many triplets with guanosine
residues also increase binding probability. In contrast, adenosine
residues have a negative effect on binding. Thus, RNA recognition
by PTBP1 is not solely dependent on pyrimidine nucleotides. The
recognition of G residues by PTB was unexpected, although some
previously characterized PTB binding sites did contain G residues
[13,44]. With this model, we can now predict PTBP1 binding
affinity to any site in the transcriptome.
PLOS Computational Biology | www.ploscompbiol.org
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Figure 5. Validation of novel PTBP1-repressed exons by RT-PCR. A. Candidate PTBP1-repressed exons with probability greater than 0.65
were validated by RT-PCR following Ptbp1 knockdown. Data shown are averages 6 standard error of PSI (Percent of Spliced In) from biological
triplicates. Statistical analysis was performed using paired one-tailed Student’s t-test (p-values,0.01**, ,0.05*). B. Exons with low PTBP1 repression
probabilities (#0.2) were also validated by RT-PCR following Ptbp1 knockdown in biological triplicates.
doi:10.1371/journal.pcbi.1003442.g005

to achieve accurate predictions from the model. However, treating
these as a separate exon class improves the prediction of PTBP1
repression. We find that for probability scores above 0.65 the
model is strongly predictive of PTBP1 repression. Applying this
criterion across the transcriptome, we identified hundreds of new
PTBP1 target exons.
Alternative exons are generally regulated by multiple proteins
acting in combination, and a particular exon will often be subject
to both positive and negative regulation by antagonistic factors.
For a model based on one factor, these other proteins will
confound predictions. Exons with high PTBP1 binding scores may
be counteracted by antagonistic factors in some cell types.
Alternatively, synergistic factors may allow an exon with a
relatively weak binding site to still recruit PTBP1. Thus, a model
based on one factor will be limited in its predictive power. In this
study, our intent was to measure the effect of PTBP1 binding alone
before considering the contributions of other factors. The logistic
modeling allowed the contributions of different binding site
placements to PTBP1 regulation to be measured.
Several studies have used Bayesian models to dissect the
regulatory properties of exons [7,54]. These models can generate
accurate predictions by incorporating a wide variety of sequence,
expression and conservation data. However, because so many
disparate variables are incorporated, it can be difficult to draw
mechanistic conclusions from these models regarding any one
protein. For example, the presence of high pyrimidine density
upstream from the branch point can be predictive of exons
showing neuronal specific inclusion [7,55]. This is presumably in
part due to many neuronal exons being regulated by PTBP1 and
PTBP2. However, a subset of these exons may be regulated by
other factors with pyrimidine rich binding sites. In the long term, it
will be most accurate to develop predictive binding models for
each protein, similar to the PTBP1 model here, and then to
incorporate each of these binding models into a larger network
model. Such an approach will allow the analysis of the many
overlapping regulatory programs controlled by RNA binding
proteins.

identify higher affinity sites but does not consider all elements or
rank them. Crosslinking-immunoprecipitation experiments allow
large numbers of binding regions to be identified. However, not all
the sequence within a CLIP tag will be contacting the protein and
it is difficult to relate CLIP signals to binding affinity. The HMM
allowed the individual assessment of different short elements
within the CLIP clusters, showing that they segregated into two
states. The ranking of the triplets for their contributions to one of
these states yielded a model where complex clusters of short
elements could be assessed for binding and yielded accurate
predictions of binding affinity. Many RNA binding proteins are
similar to PTBP1 in having multiple domains that may each make
different base specific contacts with RNA. The widespread
generation of CLIP-seq datasets will allow the modeling of RNA
recognition by almost any protein based on a large number of
known binding sites.
Using the same modeling approach, we also developed a
binding model for PTBP2 (neuronal PTB) using a published
PTBP2 CLIP dataset [49]. PTBP2 is about 70% identical to
PTBP1 in sequence, and has only two amino acid changes among
the residues making direct contact with RNA [17]. We found that
the binding models for two PTB proteins were also nearly identical
indicating that the two proteins are likely to differ more in their
protein/protein interactions than in their RNA binding sites (Data
not shown).

Defining PTBP1 target exons
Several PTBP1 target exons have been analyzed in detail
[17,50]. These exons vary in the placement and action of their
PTBP1 binding sites. It is common for PTBP1-repressed exons to
have a binding site upstream, often encompassing the branch
point of the 39 splice site [39]. Exons can also be repressed by
PTBP1 binding within the exon [19,32,33]. Other exons contain
downstream binding sites that are needed in conjunction with an
upstream site to achieve splicing repression [51,52,53]. Although
acting as a repressor for most of its targets, PTBP1 also activates
the splicing of a group of exons. There have been divergent reports
about placement of PTBP1 binding sites needed to mediate
PTBP1 enhancement of splicing. The PTBP1 binding model
allowed us to examine PTBP1 binding site placement across a
large set of known PTBP1 target exons. Nearly all exons had
predicted high affinity PTBP1 binding sites nearby. We found that
more than half of PTBP1 repressed exons have high affinity
binding sites upstream, and a fraction of PTBP1 enhanced exons
have high affinity sites downstream. These exons fit with recent
results on several other splicing regulators where the placement of
the binding site determines the direction of the regulatory effect
[12,14,34]. However, for PTBP1 these rules are not so clear. Some
PTBP1 repressed exons have their strongest predicted binding site
downstream or within the exon. These results indicate that there
are fundamental differences between the mechanisms of PTBP1
mediated splicing regulation, and those governing regulation by
certain other splicing factors.
To quantify the predictive value of the PTBP1 binding scores
for PTBP1 repression, we built a logistic model for PTBP1
regulation. For exons repressed by PTBP1, binding scores for the
upstream, downstream and exon sequences all contribute to the
probability of repression. Exons enhanced by PTBP1 were too few
PLOS Computational Biology | www.ploscompbiol.org

Materials and Methods
Hidden Markov Model for PTBP1 binding affinity
prediction
A Hidden Markov Model (HMM) was designed and trained by
an expectation–maximization (EM) method (Baum-Welch algorithm) using published PTBP1 CLIP data [13,29,30]. In total,
48,604 PTBP1-CLIP cluster sequences were used to train model
parameters. During the training step, multiple initial values were
tested to avoid a local maximum problem. Trained parameters
included emission probabilities for nucleotide triplets, initial
probabilities and transition probabilities between states [29,30].
The trained model was used to score RNA sequences. The raw
PTBP1 binding score is defined as a log-odds ratio that compares
the score of a sequence from the HMM over the score from a
background model. Since CLIP experiments do not have an
inherent corresponding negative dataset, we generated computational negative datasets and tested different background models
(Figure S4). We found that a background model that values all
triplets equally yielded the most accurate binding scores [29]. Raw
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Figure 6. Large-scale validation of novel PTBP1-repressed exons by RNA-seq. A. Validation of the PTBP1 splicing model using RNA-seq.
After Ptbp1 knockdown, we performed RNA-seq experiments and estimated changes in PSI (Percent of Spliced In) for 573 cassette exons. The graph
shows average delta PSI values for exons, grouped by their probabilities to be repressed by PTBP1. The number of exons in the corresponding
probability bin is given by n. P-values were calculated from one-tailed Student’s t-test. B. A genome browser screenshot of a novel PTBP1-regulated
exon: exon 2 of the Kcnq2 gene. For whole internal mouse exons, we created custom genome browser tracks to visualize the PTBP1 splicing model
and mapped RNA seq reads.
doi:10.1371/journal.pcbi.1003442.g006
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with canonical splice sites (GU-AG). An exon was classified as
PTBP1 repressed or enhanced when 1) the inclusion level (PSI) of
its minor isoform was greater than 5% in both the control and
knock-down samples and 2) the inclusion level of its minor isoform
was changed by 30% or more in the Ptbp1 knock down condition
compared to the control sample. Next, we collected sequence
features for each exon and its flanking exons. The features
included PTBP1 binding scores, 59 and 39 splice site strengths,
exon/intron lengths, and word frequencies. The PTBP1 binding
scores were calculated from the PTBP1 binding model described
above. The strength of splice sites was calculated by the splice-site
analyzer tool [37]. Using a mouse whole internal exon set, we
normalized features and fed them into the model. The PTBP1
splicing model is based on a multinomial logistic regression
framework using the following steps: 1) selection of initial variables
with a moderate level of association (p-value from t-test,0.25), 2)
removal of outlier exons, 3) stepwise variable selection [38]. We
scored mouse internal exons with the trained PTBP1 splicing
model and validated candidate exons with RT-PCR and RNA-seq
experiments. Exons from the training set were excluded from the
validation.

scores were further normalized and converted to z-scores. For the
69 mer RNA sequences used in binding assays, scores were
normalized by 100,000 random sequences with same length
(Figure S3). This yielded very accurate predictions of binding
affinity (Figure 2).
When considering binding scores in genomic sequence, exons
and upstream or downstream intron regions have different base
compositions and will yield different average binding scores. Thus,
to score binding sites adjacent to possible regulated exons, it is
more informative to score sites relative to equivalent sequence
regions. From the annotated mouse genome, we retrieved 168,111
internal exons and their flanking introns as separate sequence sets
using a python library, Pygr. We scored log odds of these sequences
with the trained model. Since the lengths and base compositions of
intronic and exonic sequences are different, and binding scores
automatically increase with length (Figure S13) [29], we grouped
sequences by their location and sequences in each group were
sorted according to length into bins of 1000 sequences each. The
average score and standard deviation were determined for each
bin. These values were used to transform the raw scores into
z-scores for each upstream intron, downstream intron, and exon
sequence. We localized the PTBP1 binding sites along each RNA
sequence using the Viterbi algorithm [29,30].

Validation of exon candidates by RT-PCR and RNA-seq
To test alternative splicing events for candidate exons, we
assayed exon inclusion levels in cells following Ptbp1, Ptbp2, and
double Ptbp1 & Ptbp2 knock down. The knockdown experiment
was performed as described previously with minor modification
[20]. Mouse neuroblastoma (N2A) cells were cultured in DMEM
with 10% FBS and 2 mM L-glutamine. At 70 to 80% confluency,
cells were trypsinized and suspended in the growth medium.
DNA–Lipofectamine 2k (Invitrogen) complexes were prepared
and mixed with cells in a tube according to manufacturer’s
instructions. Tubes were incubated for 5 h with mixing every half
hour. Then cells were centrifuged and cultured in plates for 3 d.
Proteins and RNA was extracted from collected cells. Protein
samples were subjected to fluorescence immunoblotting to
monitor knockdown efficiency of Ptbp1 and Ptbp2. Total RNA
was collected using Trizol (Invitrogen) according to the manufacturer’s instructions. The RNA was further treated with DNase I to
avoid DNA contamination. For RT-PCR (Reverse TranscriptionPCR) assays, the RNA was reverse transcribed to cDNA with
random hexamers using SuperScript enzyme (Invitrogen) following the manufacturer’s instructions. PCR reactions were performed to assay alternative splicing of particular target exons.
First, forward and reverse PCR primers were designed for the
flanking exons using PRIMER3 program [56]. To label PCR
products, a 59 fluorescent-labeled universal primer (59-FAMCGTCGCCGTCCAGCTCGACCAG-39) was added to the PCR
reaction and a universal priming site was introduced to the 59 end
of the forward primer (59-CGTCGCCGTCCAGCTCGACCAGForward Primer-39). Each PCR reaction (15 mL) was carried out
with 1.5 picomole of the forward primer and 6.75 picomole of the
reverse and universal primers [57]. PCR amplification proceeded
with an initial denaturation at 94uC for 4 m followed by 24 cycles
of 94uC for 30 s, at a melting temperature of the reverse primer for
45 s, and 72uC for 45 s, with a final extension step at 72uC for
10 m. The samples were mixed with 26 formamide buffer
(Formamide with 1 mM EDTA pH 8.0) and denatured at 95uC
for 5 min. Then samples were chilled on ice and run on 8%
denaturing polyacrylamide gels. Gels were directly scanned by
Typhoon and quantified by ImageQuant program.
RNA-seq libraries were constructed following standard protocols (Illumina TruSeq RNA Sample Prep Kit). To make strandspecific libraries, we added two extra steps to the protocol [41].

Validation of PTBP1 binding model scores by binding
assay
To test predicted PTBP1 binding scores, we selected thirteen
mouse exon/intron RNA sequences (69 nucleotides) exhibiting a
range scores. In the selection, other sequence features such as
secondary structure were not considered. Target RNAs were
transcribed in vitro from dsDNA using T7 RNA polymerase and
subjected to an electrophoretic mobility shift assay (EMSA).
During the transcription, radioactive a-32P UTP was incorporated into RNA to visualize the probes. The RNA probes were then
denatured for 2 min at 85uC and cooled down on ice immediately
to reduce secondary structure formation. Binding assays were
carried out as previously described with some modifications [27].
Specifically, each gel mobility shift reaction (10 mL) contained the
indicated amounts of recombinant human PTBP1 in 6 mL DG
buffer (20 mM Hepes-KOH ph 7.9, 20% glycerol, 80 mM
potassium glutamate, 0.2 mM EDTA, 0.2 mM PMSF), 1 mL
22 mM MgCl2, 1 mL 0.5 mg/ml tRNA, 0.5 mL RNase inhibitor
(20 unit, RNaseOut from invitrogen), 0.5 mL DEPC treated H2O,
and 1 mL 100 nM RNA probe. At first, all reaction components
excluding RNase inhibitor, tRNA, and RNA probes were mixed
and incubated for 8 min at 30uC. Then RNase inhibitor and
tRNA were added and mixed. RNA probe was then added and
the reaction was incubated for an additional 15 min. The
reactions were put on ice for 5 min and mixed with 1.2 mL
glycerol loading dye (30% glycerol). They were separated on 8%
native polyacrylamide gels with 25 mM Tris-Gly running buffer in
a cold room. Gels were dried and exposed to a phosphor screen.
Then images were scanned using Typhoon 9410 and quantified
using ImageQuant TL program (GE Lifesciences). The apparent
Kd values were estimated by fitting the data to non-linear curves
using Prism software.

Logistic regression model for PTBP1 dependent exon
prediction
An exon training set was compiled from previous microarray
and RT-PCR experiments [20,35]. The training set was composed
with 68 PTBP1 repressed, 37 PTBP1 enhanced, and 69 nonPTBP1 regulated simple cassette exons. We only considered exons
PLOS Computational Biology | www.ploscompbiol.org

15

January 2014 | Volume 10 | Issue 1 | e1003442

Prediction of PTBP1 Binding and Splicing Targets

slightly improves the linear fit (20.91 vs. 20.95) for some strong
binders. However, it wrongly predicted some binders as nonbinders, which reduced the rank correlation (20.95 to 20.90).
The two shuffled models did not perform well.
(TIF)

After first strand cDNA synthesis, remaining dNTPs were
removed by a size selection on beads (AMPure XP). Secondstrand cDNA was synthesized with a dNTP mix containing dUTP
instead of dTTP. The reaction contained samples eluted in 50 ml
resuspension buffer, 2 ml 56 FS buffer, 1 ml 50 mM MgCl2, 1 ml
100 mM DTT, 2 ml 10 mM dUTP nucleotides mix, 15 ml Second
Strand Buffer (Invitrogen), 0.5 ml E.coli DNA Ligase (10 U/
ml;NEB), 0.5 ml RNase H (2 U/ml;Invitrogen), 2 ml DNA E.coli
Polymerase I (10 U/ml;NEB). The reaction was incubated for 2 h
at 16uC. After sequencing adaptors were ligated, 1 ml USER
(Uracil-Specific Excision Reagent enzyme; NEB) was added to
reactions to degrade the second strand cDNA. The samples were
incubated for 15 min at 37uC and the reaction were inactivated at
94uC for 5 min. The samples were put in ice and then subjected to
PCR amplification. Average size of inserts was about 225 bp and
the libraries were subjected to 100 bp paired-end sequencing
(Illumina HiSeq2000 platform). Using SpliceTrap [42], 60–65%
of reads were mapped to exon duos or trios. In total, 180M
(179,511,116) and 145M (145,334,711) paired end reads were
used to infer exon inclusion ratios in the control and Ptbp1
knockdown conditions, respectively. The data have been deposited
in NCBI’s Gene Expression Omnibus [58] and are accessible
through GEO Series accession number GSE45119.

Figure S5 Correlations of particular sequence features

with PTBP1 repression. For PTBP1-repressed and PTBP1
non-regulated exons, we calculated scores for sequence features
and determined the fraction of PTBP1-repressed exons in each
score bin. Shown are the graphs for the 39 splice site score, and the
PTBP1 binding scores in the upstream intron, the exon, and the
downstream intron plotted against the percent of exons within the
score bin that are PTBP1-repressed.
(TIF)
Figure S6 Performance of PTBP1-dependent splicing
models. A. Receiver Operating Characteristic Curves in a leaveone-out cross validation for each logit: exon repression (left) and
exon enhancement (right). B. Sensitivity and specificity plotted
across the whole threshold range. Sensitivity is defined as the
percent of true repressed exons that are correctly predicted as
repressed at the corresponding threshold. Specificity is defined as
the percent of actual non-repressed exons that are correctly
predicted as non-repressed at the corresponding threshold.
(TIF)

Supporting Information
Figure S1 Five-fold cross-validation of the PTBP1

Figure S7 ShRNA mediated depletion of PTBP1 and
PTBP2. Duplicate immunoblots after shRNA knockdown of
PTBP1, PTBP2 or both proteins. Note that depletion of PTBP1
induces expression of PTBP2 as observed previously. Numbers
above each lane indicate the fluorescence intensity for PTBP1 or
PTBP2 relative to the control lane.
(TIF)

binding model using Hela CLIP clusters. To test the two
state model of binding and non-binding triplets, we divided the
CLIP-data to the five subsets. In each plot, four sub sets were used
in training the model and one subset was subjected to scoring. We
then compared scores from the CLIP-subset sequences to random
sequences picked from same genic regions that contained the
CLIP clusters. As shown, sequences from CLIP-subset generated
significantly higher scores than random. The results indicate that
the triplets identified by the HMM as predictive of state 1 are
predictive of PTBP1 CLIP sites and thus of protein binding.
(TIF)

Figure S8 Characteristics of false positive exons. A.
Exon inclusion was measured for three false positives exons after
Ptbp1 knockdown (left), or Ptbp2 knockdown, and Ptbp1 & Ptbp2
double knockdown (right). P-values were calculated from biological triplicates using paired one-tailed t-tests. B. False positive
exons exhibit higher PSI values prior to PTBP1 depletion. Box
plot of exon inclusion for twenty-nine false positive exons showing
little change in splicing by RNA-seq after PTBP1 depletion (delta
PSI,5%) that score with high probability to be repressed (.0.55).
Exon inclusion levels prior to PTBP1 depletion are compared to
thirty-six true positive exons.
(TIF)

Figure S2 The density of PTBP1 binding triplets
predicted by the HMM peaks at the aligned crosslink
sites from Human ESC iCLIP clusters.
(TIF)
Figure S3 PTBP1 binding model scores and validation.
A. Summary statistics and the distribution of raw and normalized
PTBP1 binding scores for 100,000 random sequences. B.
Electrophoretic mobility shift assay of RNAs with various PTBP1
binding scores. RNAs were transcribed in vitro, incubated with
increasing concentrations of purified PTBP1 (0 to 200 nM), and
the bound and unbound RNA separated on native gels. Arrows
indicate RNA-protein complexes. The fraction of PTBP1-bound
RNA is plotted below for each RNA.
(TIF)

Figure S9 Two exons with intermediate scores for
PTBP1 repression show complex responses to PTBP1
and PTBP2 depletion. Exon inclusion was measured after
Ptbp1 depletion (left), or after Ptbp2 and Ptbp1/Ptbp2 double
depletion (right). P-values were calculated from biological
triplicates using paired one-tailed t-tests.
(TIF)

Figure S4 Evaluation of different background models
for scoring PTBP1 binding. Four background models were
evaluated. The uniform distribution model assumes equal
frequencies of triplets. The PTBP1 target gene set model used
random sequences from genes containing PTBP1 CLIP clusters.
The two shuffled models used shuffled CLIP cluster sequences
maintaining mono or di nucleotide ratios. We calculated PTBP1
binding scores based on each background model and compared
the scores to the measured dissociation constants. Based on the
rank correlation, the uniform distribution model worked best. The
PTBP1 target gene set model showed comparable performance. It
PLOS Computational Biology | www.ploscompbiol.org

Figure S10 PTBP2 dependence of predicted PTBP1
target exons. RT-PCR of high probability PTBP1 exon targets
following Ptbp2 knockdown or Ptbp2/Ptbp1 double knockdown.
Relative band intensities of the gels in triplicate on the right are
plotted on the left to show the average delta PSI 6 SE (Percent
Spliced In). P-values were calculated from paired one-tailed t-tests
with PSI values in control samples.
(TIF)
Figure S11 PTBP2 dependence of predicted non-PTBP1
target exons. RT-PCR of exon with low probabilities for PTBP1
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Table S1 Trained PTBP1 splicing regulation model. The
table presents a summary of the multinomial logistic regression
model for PTBP1 splicing regulation, including estimated
coefficients and their statistics.
(TIF)

repression (#0.2). Ptbp2 knockdown and Ptbp1/Ptbp2 double knock
down with data analysis as in Figure S10.
(TIF)
Figure S12 Boxplot of PSI (Percent of Spliced In) values
estimated from splicing sensitive microarray data for
exons expressed in mouse C2C12 myoblasts. Exons with
higher (.0.65) and lower (,0.2) repression probabilities are
compared. Exons used in the original training set were excluded
from the plot. The number of exons in the corresponding
probability bin is given by n. The p-value was calculated from a
one-tailed Student’s t-test.
(TIF)

Table S2 Enriched gene ontology categories for novel
PTBP1-repressed exons. The table lists ontology entries
enriched in genes with predicted PTBP1-repressed exons (probability score of exon repression .0.65). Whole mouse internal
exons were used as the control set, and p-value cut off was 0.05.
Gene ontology analysis was performed using the GOTM web
server.
(TIF)

Distribution of PTBP1 binding scores of
exons and introns before and after normalization.
168,111 exons and their flanking introns from the set of annotated
mouse internal exons were subjected to scoring and normalization.
Raw PTBP1 Binding scores are affected by sequence length and
base composition. To account differences in these features
between introns and exons in normalized scores, we grouped the
exons and their upstream and downstream introns separately. The
sequences in each group were sorted according to length into bins
of 1,000 sequences each. The average scores and standard
deviations were determined for each bin. These values were used
to transform the raw scores into z-scores for each sequence per
bin.
(TIF)

Figure S13
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